Skip to main content
. 2019 Apr 27;3(2):pkz026. doi: 10.1093/jncics/pkz026

Table 2.

CTC in neoadjuvant therapy: published studies with CellSearch and meta-analysis*

References No. of patients Stage Blood screened, mL CTC detection rate, %
 Correlation CTC and pCR Prognostic impact
 Detail of prognostic impact OS HR (95% CI)
Before NCT After NCT DFS OS
Studies

  • REMAGUS02

  • Pierga et al. (2008) (58)

  • Bidard et al. (23, 59) (2010, 2013)

 115 II–III 7.5 23 17 No Yes Yes n.a.

  • GEPARQUATTRO

  • Riethdorf et al. (24) (2010, 2017)

 213 I–III 7.5 21 10 No Yes Yes n.a.

  • NEOALTTO

  • Azim et al. (2013) (60)

 51 I–III 22.5 11 16 No — — n.a.

  • NEOZOTAC

  • Onstenk et al. (2015) (62)

 95 I–III 7.5 18 — No — — n.a.

  • MD Anderson

  • Hall et al. (2015) (61)

 57

  • I–III

  • (triple negative)

 7.5 — — No Yes Yes n.a.

  • MD Anderson

  • Mego et al. (2015) (63)

 77 III (T4d) 7.5 54 — No No No n.a.

  • MD Anderson

  • Hall et al. (2015) (61)

 63 III (T4d) 7.5 — 27 No Yes No n.a.

  • BEVERLY-1 and -2

  • Pierga et al. (25) (2017)

 137 III (T4d) 7.5 35 7 No Yes Yes n.a.

  • JBCRG-07

  • Ueno et al. (2018) (64)

 34 I–III 7.5 — — No Yes — n.a.
Meta-analysis

  • IMENEO

  • Bidard et al. (13) (2018)

 2156 I–III

  • 7.5

  • (mostly)

 25 17 No Yes Yes No CTC detected:

  • 1 (reference)

  • 1 CTC detected: 1.09 (0.65 to 1.69)

  • 2 CTCs detected: 2.63 (1.42 to 4.54)

  • 3–4 CTCs detected: 3.83 (2.08 to 6.66)

  • ≥5 CTCs detected: 6.25 (4.34 to 9.09)
*

CI = confidence interval; CTC = circulating tumor cells; DFS = disease-free survival; HR = hazard ratio; OS = overall survival; n.a. = not available; NCT = neoadjuvant treatment; pCR = pathological complete response; pts . patients;